Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Gynecologic Oncology

• Publication date

  1995-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/GYNO.1995.1236PMID 7672697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells

  2004cited by this paper
• Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen.

  1994cited by this paper
• Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.

  1994cited by this paper
• Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.

  1994cited by this paper
• Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

  1994cited by this paper
• Thymocyte apoptosis induced by p53-dependent and independent pathways

  1993cited by this paper
• Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity.

  1993cited by this paper
• A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines.

  1993cited by this paper
• Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance.

  1993cited by this paper
• p53 is required for radiation-induced apoptosis in mouse thymocytes

  1993cited by this paper
• Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.

  1993cited by this paper
• Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines

  1992cited by this paper
• High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

  1992cited by this paper
• Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

  1992cited by this paper
• Chemotherapy for advanced epithelial ovarian cancer.

  1992cited by this paper
• Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer.

  1992cited by this paper
• The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

  1991cited by this paper
• Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin.

  1991cited by this paper
• Participation of p53 protein in the cellular response to DNA damage.

  1991cited by this paper
• Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

  1991cited by this paper
• Pooled analysis of 3 european case‐control studies: I. Reproductive factors and risk of epithelial ovarian cancer

  1991cited by this paper
• Pooled analysis of 3 european case‐control studies of epithelial ovarian cancer: III. Oral contraceptive use

  1991cited by this paper
• Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines

  1991cited by this paper
• Ovarian cancer biology.

  1991cited by this paper
• Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).

  1990cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines.

  1990cited by this paper
• Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

  1990cited by this paper
• Sensitivity Pattern of Normal and Ha-Ras Transformed Nih3T3 Fibroblasts to Antineoplastic Drugs

  1989cited by this paper
• Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.

  1989cited by this paper
• DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.

  1989cited by this paper
• Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.

  1989cited by this paper
• cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

  1988cited by this paper
• Enhanced DNA repair and resistance to cisplatin in human ovarian cancer.

  1988cited by this paper
• Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

  1988cited by this paper
• Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes.

  1988cited by this paper
• Tumor heterogeneity and drug resistance.

  1986cited by this paper
• The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

  1984cited by this paper
• Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells.

  1983cited by this paper
• The role of DNA repair in the recovery of human cells from cisplatin toxicity.

  1981cited by this paper
• Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine.

  1980cited by this paper
• A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

  1979cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Proliferation-dependent cytotoxicity of anticancer agents: a review.

  1975cited by this paper

• The role of sulfur in platinum anticancer chemotherapy.

  2007cites this paper
• Chemical, Pharmacokinetic and Biological Aspects of Platinum-Based Drugs

  2005cites this paper
• Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance.

  2003cites this paper
• Animal Cell Types, Ovarian Cells

  2003cites this paper
• An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells.

  1998cites this paper
• Cellular and molecular determinants of cisplatin resistance.

  1998cites this paper